Literature DB >> 21434688

Structural characterization of three novel hydroxamate-based zinc chelating inhibitors of the Clostridium botulinum serotype A neurotoxin light chain metalloprotease reveals a compact binding site resulting from 60/70 loop flexibility.

Aaron A Thompson1, Guan-Sheng Jiao, Seongjin Kim, April Thai, Lynne Cregar-Hernandez, Stephen A Margosiak, Alan T Johnson, Gye Won Han, Sean O'Malley, Raymond C Stevens.   

Abstract

Neurotoxins synthesized by Clostridium botulinum bacteria (BoNT), the etiological agent of human botulism, are extremely toxic proteins making them high-risk agents for bioterrorism. Small molecule inhibitor development has been focused on the light chain zinc-dependent metalloprotease domain of the neurotoxin, an effort that has been hampered by its relatively flexible active site. Developed in concert with structure--activity relationship studies, the X-ray crystal structures of the complex of BoNT serotype A light chain (BoNT/A LC) with three different micromolar-potency hydroxamate-based inhibitors are reported here. Comparison with an unliganded BoNT/A LC structure reveals significant changes in the active site as a result of binding by the unique inhibitor scaffolds. The 60/70 loop at the opening of the active site pocket undergoes the largest conformational change, presumably through an induced-fit mechanism, resulting in the most compact catalytic pocket observed in all known BoNT/A LC structures.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21434688      PMCID: PMC3092028          DOI: 10.1021/bi2001483

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  29 in total

1.  The penultimate rotamer library.

Authors:  S C Lovell; J M Word; J S Richardson; D C Richardson
Journal:  Proteins       Date:  2000-08-15

2.  Intimate details of the most poisonous poison.

Authors:  B R Singh
Journal:  Nat Struct Biol       Date:  2000-08

Review 3.  The structure and mode of action of different botulinum toxins.

Authors:  J O Dolly; K R Aoki
Journal:  Eur J Neurol       Date:  2006-12       Impact factor: 6.089

4.  Conformational sampling of the botulinum neurotoxin serotype A light chain: implications for inhibitor binding.

Authors:  James C Burnett; James J Schmidt; Connor F McGrath; Tam L Nguyen; Ann R Hermone; Rekha G Panchal; Jonathan L Vennerstrom; Krishna Kodukula; Daniel W Zaharevitz; Rick Gussio; Sina Bavari
Journal:  Bioorg Med Chem       Date:  2005-01-17       Impact factor: 3.641

5.  Inhibition of metalloprotease botulinum serotype A from a pseudo-peptide binding mode to a small molecule that is active in primary neurons.

Authors:  James C Burnett; Gordon Ruthel; Christian M Stegmann; Rekha G Panchal; Tam L Nguyen; Ann R Hermone; Robert G Stafford; Douglas J Lane; Tara A Kenny; Connor F McGrath; Peter Wipf; Andrea M Stahl; James J Schmidt; Rick Gussio; Axel T Brunger; Sina Bavari
Journal:  J Biol Chem       Date:  2006-11-08       Impact factor: 5.157

6.  Optimal description of a protein structure in terms of multiple groups undergoing TLS motion.

Authors:  Jay Painter; Ethan A Merritt
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2006-03-18

7.  Substrate recognition strategy for botulinum neurotoxin serotype A.

Authors:  Mark A Breidenbach; Axel T Brunger
Journal:  Nature       Date:  2004-12-12       Impact factor: 49.962

8.  Unique substrate recognition by botulinum neurotoxins serotypes A and E.

Authors:  Sheng Chen; Joseph T Barbieri
Journal:  J Biol Chem       Date:  2006-02-14       Impact factor: 5.157

9.  Structures of Clostridium botulinum Neurotoxin Serotype A Light Chain complexed with small-molecule inhibitors highlight active-site flexibility.

Authors:  Nicholas R Silvaggi; Grant E Boldt; Mark S Hixon; Jack P Kennedy; Saul Tzipori; Kim D Janda; Karen N Allen
Journal:  Chem Biol       Date:  2007-05

Review 10.  Presynaptic enzymatic neurotoxins.

Authors:  Ornella Rossetto; Laura Morbiato; Paola Caccin; Michela Rigoni; Cesare Montecucco
Journal:  J Neurochem       Date:  2006-06       Impact factor: 5.372

View more
  10 in total

1.  Structural insight into exosite binding and discovery of novel exosite inhibitors of botulinum neurotoxin serotype A through in silico screening.

Authors:  Xin Hu; Patricia M Legler; Noel Southall; David J Maloney; Anton Simeonov; Ajit Jadhav
Journal:  J Comput Aided Mol Des       Date:  2014-06-24       Impact factor: 3.686

Review 2.  Targeting Metalloenzymes for Therapeutic Intervention.

Authors:  Allie Y Chen; Rebecca N Adamek; Benjamin L Dick; Cy V Credille; Christine N Morrison; Seth M Cohen
Journal:  Chem Rev       Date:  2018-09-07       Impact factor: 60.622

3.  Use of Crystallography and Molecular Modeling for the Inhibition of the Botulinum Neurotoxin A Protease.

Authors:  Lewis D Turner; Alexander L Nielsen; Lucy Lin; Antonio J Campedelli; Nicholas R Silvaggi; Jason S Chen; Amanda E Wakefield; Karen N Allen; Kim D Janda
Journal:  ACS Med Chem Lett       Date:  2021-07-28       Impact factor: 4.632

4.  The C terminus of the catalytic domain of type A botulinum neurotoxin may facilitate product release from the active site.

Authors:  Rahman M Mizanur; Verna Frasca; Subramanyam Swaminathan; Sina Bavari; Robert Webb; Leonard A Smith; S Ashraf Ahmed
Journal:  J Biol Chem       Date:  2013-06-18       Impact factor: 5.157

5.  Natural Compounds and Their Analogues as Potent Antidotes against the Most Poisonous Bacterial Toxin.

Authors:  Kruti B Patel; Shuowei Cai; Michael Adler; Brajendra K Singh; Virinder S Parmar; Bal Ram Singh
Journal:  Appl Environ Microbiol       Date:  2018-11-30       Impact factor: 4.792

6.  Discovery of Dipeptides as Potent Botulinum Neurotoxin A Light-Chain Inhibitors.

Authors:  Martin Amezcua; Ricardo S Cruz; Alex Ku; Wilfred Moran; Marcos E Ortega; Nicholas T Salzameda
Journal:  ACS Med Chem Lett       Date:  2021-01-27       Impact factor: 4.345

7.  Identification of clinically viable quinolinol inhibitors of botulinum neurotoxin A light chain.

Authors:  Dejan Caglič; Michelle C Krutein; Kristin M Bompiani; Deborah J Barlow; Galit Benoni; Jeffrey C Pelletier; Allen B Reitz; Luke L Lairson; Karen L Houseknecht; Garry R Smith; Tobin J Dickerson
Journal:  J Med Chem       Date:  2014-01-15       Impact factor: 7.446

8.  In Silico and Experimental ADAM17 Kinetic Modeling as Basis for Future Screening System for Modulators.

Authors:  Marian Bienstein; Dmitriy Minond; Ulrich Schwaneberg; Mehdi D Davari; Daniela Yildiz
Journal:  Int J Mol Sci       Date:  2022-01-25       Impact factor: 5.923

9.  Small-molecule quinolinol inhibitor identified provides protection against BoNT/A in mice.

Authors:  Padma Singh; Manglesh Kumar Singh; Dilip Chaudhary; Vinita Chauhan; Pranay Bharadwaj; Apurva Pandey; Nisha Upadhyay; Ram Kumar Dhaked
Journal:  PLoS One       Date:  2012-10-11       Impact factor: 3.240

10.  Second generation steroidal 4-aminoquinolines are potent, dual-target inhibitors of the botulinum neurotoxin serotype A metalloprotease and P. falciparum malaria.

Authors:  Milica Videnović; Dejan M Opsenica; James C Burnett; Laura Gomba; Jonathan E Nuss; Zivota Selaković; Jelena Konstantinović; Maja Krstić; Sandra Segan; Mario Zlatović; Richard J Sciotti; Sina Bavari; Bogdan A Solaja
Journal:  J Med Chem       Date:  2014-05-01       Impact factor: 7.446

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.